ServicenavigationHauptnavigationTrailKarteikarten

Research unit
INNOSUISSE
Project number
52533.1 IP-LS
Project title
Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)
Project status Finished
 
Start date 01.04.2021
End date 01.10.2022
 
Granted total costs 1'289'270.66  CHF
Section 60 Life Sciences
Project category Project
Research type Applied research and development
NABS classification Industrial production and technology
 
Research disciplines
100 % B007 Medicine (human and vertebrates)
Last modification of the project